Back to Journals » Integrated Blood Pressure Control » Volume 1

Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study

Authors Kabakci G, Koylan N, Ilerigelen B, Kozan O, Buyukozturk K

Published 2 November 2008 Volume 2008:1 Pages 5—13

DOI https://doi.org/10.2147/IBPC.S3809

Review by Single-blind

Peer reviewer comments 3


Giray Kabakci1, Nevres Koylan2, Baris Ilerigelen3, Omer Kozan4, Kemalettin Buyukozturk2 on behalf of the ICEBERG Investigators

1Hacettepe University, Hacettepe School of Medicine, Department of Cardiology, Ankara, Turkey; 2Istanbul University, Istanbul School of Medicine, Department of Cardiology, Istanbul, Turkey; 3Istanbul University, Cerrahpasa School of Medicine, Department of Cardiology, Istanbul, Turkey; 4Dokuz Eylul University, Dokuz Eylul School of Medicine, Department of Cardiology, Izmir, Turkey

Background: Hypertension, dyslipidemia, and other cardiovascular risk factors are linked epidemiologically, clinically, and metabolically. Intensive/Initial Cardiovascular Examination regarding Blood Pressure levels, Evaluation of Risk Groups (ICEBERG) study focuses on the effect of dyslipidemia on cardiovascular risk evaluation and association of lipid profile with other risk factors.

Patients and methods: The ICEBERG study consisted of two sub-protocols: ICEBERG-1, conducted at 20 university hospitals (Referral Group) and ICEBERG-2, conducted at 197 primary healthcare centers (Primary Care Group). Sub-protocol had two patient profiles: patients previously diagnosed with essential hypertension and under medical treatment (Treated Group) and patients with systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, with no antihypertensive treatment for at least 3 months before inclusion (Untreated Group). Dyslipidemia was evaluated and cardiovascular risk stratification was performed according to ESC/ESH guidelines.

Results: More than half of the treated and untreated subjects were classified into high or very high cardiovascular risk groups. In a total of 1817 patients, the percentage of patients in “high” plus “very high” added risk groups increased to 55.2% in Treated Referral Group (p < 0.001), to 62.6% in Untreated Referral Group (p = 0.25) and to 60.7% in Untreated Primary Care Group (p < 0.001), by re-evaluation of patients’ lipid values.

Conclusions: Serum lipid levels are useful in stratifying hypertensive patients into cardiovascular risk groups more accurately, for appropriate antihypertensive treatment.

Keywords: hypertension, dyslipidemia, cardiovascular disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]